PMID- 29049330
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 10
DP  - 2017
TI  - The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand
      population.
PG  - e0186424
LID - 10.1371/journal.pone.0186424 [doi]
AB  - BACKGROUND: The incidence of oropharyngeal cancer (OPC) in New Zealand (NZ) has
      more than doubled over the last 14 years with 126 cases in 2010. Overseas studies
      have shown that human papillomavirus (HPV) plays a significant role in the
      development of these cancers. However, the role of HPV in OPC and the burden on
      the NZ health system is unclear. AIM: The aim of the study was to determine the
      prevalence and the genotypes of HPV associated with OPC in New Zealand. METHODS: 
      In this study, 621 OPC were identified from cancer registry data from 1996-98,
      2003-05, and 2010-12. Biopsies of 267 cases were then retrieved from laboratories
      throughout New Zealand. p16 immunohistochemistry and a human beta globin PCR were
      performed on all specimens. HPV genotyping was performed on all beta globin
      positive specimens using real-time PCR with melt analysis. RESULTS: Using a
      p16/PCR algorithm, 77.9% (95% CI: 71.1-83.5%) of cases were attributable to HPV. 
      Of these, 98.5% were HPV 16 positive. There was also one case each of HPV 33 and 
      35. The percentage of HPV positive cases increased from 61.9% (95% CI: 40.9%-
      79.2%) in 1996-98 to 87.5% (95% CI: 79.8%- 92.5%) in 2010-12. Results from the
      multivariable model, adjusted for sex and ethnicity found statistically
      significant associations between HPV positivity and timeframe (OR: 5.65, 95% CI: 
      2.60-12.30, 2010-12 vs 1996-98), and between HPV positivity and patient age (OR: 
      0.55, 95% CI: 0.33-0.99, >/=61 years vs </=60 years). CONCLUSIONS: This data is
      consistent with data from other developed countries showing an increase in cases 
      of HPV positive OPC in New Zealand, and the majority of cases being attributable 
      to HPV 16. These results support the recent inclusion of males into the
      nationally funded immunization schedule for Gardasil(R) 9.
FAU - Lucas-Roxburgh, Rebecca
AU  - Lucas-Roxburgh R
AUID- ORCID: http://orcid.org/0000-0001-8080-3935
AD  - Institute of Veterinary, Animal, and Biomedical Sciences, Massey University,
      Palmerston North, New Zealand.
FAU - Benschop, Jackie
AU  - Benschop J
AD  - Molecular Epidemiology and Public Health Laboratory, Hopkirk Research Institute, 
      Massey University, Palmerston North, New Zealand.
FAU - Lockett, Bruce
AU  - Lockett B
AD  - Histopathology Department, MedLab Central Ltd, Palmerston North, New Zealand.
FAU - van den Heever, Ursula
AU  - van den Heever U
AD  - Histopathology Department, MedLab Central Ltd, Palmerston North, New Zealand.
FAU - Williams, Ruth
AU  - Williams R
AD  - Histopathology Department, MedLab Central Ltd, Palmerston North, New Zealand.
FAU - Howe, Laryssa
AU  - Howe L
AD  - Institute of Veterinary, Animal, and Biomedical Sciences, Massey University,
      Palmerston North, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Alphapapillomavirus/genetics/*isolation & purification
MH  - DNA, Viral/genetics
MH  - Humans
MH  - New Zealand/epidemiology
MH  - Oropharyngeal Neoplasms/epidemiology/*virology
MH  - Real-Time Polymerase Chain Reaction
MH  - Registries
PMC - PMC5648183
EDAT- 2017/10/20 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/10/20 06:00
PHST- 2017/06/13 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/10/20 06:00 [entrez]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
AID - 10.1371/journal.pone.0186424 [doi]
AID - PONE-D-17-22645 [pii]
PST - epublish
SO  - PLoS One. 2017 Oct 19;12(10):e0186424. doi: 10.1371/journal.pone.0186424.
      eCollection 2017.